statistiche ricercatore

CANDUCCI, FILIPPO

Distribuzione geografica

Continente	#
NA - Nord America	5.076
EU - Europa	2.822
AS - Asia	641
Continente sconosciuto - Info sul continente non disponibili	9
OC - Oceania	3
AF - Africa	1
SA - Sud America	1
Totale	8.553

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	4.980
IT - Italia	1.652
UA - Ucraina	502
TR - Turchia	314
SE - Svezia	246
VN - Vietnam	169
CN - Cina	138
FI - Finlandia	125
CA - Canada	96
DE - Germania	96
IE - Irlanda	92
GB - Regno Unito	61
FR - Francia	32
JP - Giappone	18
BE - Belgio	9
EU - Europa	9
NL - Olanda	5
NZ - Nuova Zelanda	2
AU - Australia	1
CL - Cile	1
EG - Egitto	1
ES - Italia	1
ID - Indonesia	1
IN - India	1
RU - Federazione Russa	1
Totale	8.553

Salva come PNG Salva come JPEG

Città	#
Milan	1.276
Fairfield	841
Woodbridge	508
Jacksonville	428
Houston	387
Ashburn	371
Chandler	350
Ann Arbor	313
Seattle	301
Cambridge	298
Wilmington	274
Nyköping	163
Princeton	144
Izmir	141
Dearborn	137
Toronto	95
Dong Ket	93
Dublin	89
Rome	69
Como	54
San Diego	46
Boardman	41
Beijing	21
Ogden	20
Nanjing	19
Tokyo	17
Kunming	16
Hefei	15
London	15
Brussels	9
Washington	9
Verona	8
Chengdu	7
Jinan	7
Norwalk	7
Chicago	6
Nanchang	6
Ponte Lambro	6
Guangzhou	5
Hounslow	5
Kilburn	4
Redmond	4
Fuzhou	3
Huzhou	3
Los Angeles	3
New York	3
Redwood City	3
Tübingen	3
Auckland	2
Baotou	2
Cagliari	2
Düsseldorf	2
Mannheim	2
Monserrato	2
Ningbo	2
San Mateo	2
Selargius	2
Shanghai	2
Shenyang	2
Velletri	2
Wuhan	2
Amsterdam	1
Brooklyn	1
Cantù	1
Cesena	1
Changsha	1
Chiswick	1
Chongqing	1
Concorezzo	1
Florence	1
Frankfurt am Main	1
Glasgow	1
Groningen	1
Harbin	1
Hebei	1
Indiana	1
Jinhua	1
Kuujjuarapik	1
Lappeenranta	1
Liverpool	1
Macon	1
Magnago	1
Mammola	1
Miami	1
Mountain View	1
Phoenix	1
Putian	1
Quzhou	1
San Francisco	1
Seaside Heights	1
Surabaya	1
Torino	1
Trieste	1
Tuam	1
Turin	1
Waterford	1
Wenzhou	1
Xian	1
Xining	1
Yellow Springs	1
Totale	6.708

Salva come PNG Salva come JPEG

Nome	#
Kuwanon-L as a New Allosteric HIV-1 Integrase Inhibitor: Molecular Modeling and Biological Evaluation	176
One drug for two targets: Biological evaluation of antiretroviral agents endowed with antiproliferative activity	171
The Microbiome of the Prostate Tumor Microenvironment	163
Performance of commonly used genotypic assays and comparison with phenotypic assays of HIV-1 coreceptor tropism in acutely HIV-1-infected patients.	158
Virological rebound in human immunodeficiency virus-infected patients with or without residual viraemia: results from an extended follow-up	154
Inhibition of HIV-1 Reverse Transcriptase Dimerization by Small Molecules	154
Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL-authors' response	147
Integrase and fusion inhibitors transmitted drug resistance in naive patients with recent diagnosis of HIV-1 infection.	143
Helicobacter pylori treatment: a role for probiotics?	142
Antigen-driven evolution of B lymphocytes in coronary atherosclerotic plaques.	142
Immunological recovery after 24 weeks of antiretroviral therapy in patients with x4 virus during primary hiv infection	142
Duodenal mucosa of patients with type 1 diabetes shows distinctive inflammatory profile and microbiota	142
Use of genotype MTBDR assay for molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis clinical strains isolated in Italy.	142
Cross-reacting antibacterial auto-antibodies are produced within coronary atherosclerotic plaques of acute coronary syndrome patients.	141
The interplay of extracellular matrix and microbiome in urothelial bladder cancer	141
Adaptive immunity against gut microbiota enhances apoE-mediated immune regulation and reduces atherosclerosis and western-diet-related inflammation	137
Monoclonal antibodies isolated from human B cells neutralize a broad range of H1 subtype influenza A viruses including swine-origin Influenza virus (S-OIV).	135
Pregnancy and H1N1 infection.	134
Onset of Berger disease after Staphylococcus aureus infection: septic arthritis after anterior cruciate ligament reconstruction.	133
Coronaviridae and SARS-associated coronavirus strain HSR1.	132
A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates.	132
Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy: a pilot study.	131
Probiotics and Helicobacter pylori eradication.	131
Oral probiotic VSL#3 prevents autoimmune diabetes by modulating microbiota and promoting indoleamine 2,3-dioxygenase-enriched tolerogenic intestinal environment	130
Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies.	129
Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience.	129
GB virus C and survival in persons with HIV infection	128
Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption.	128
Natural Product Kuwanon-L Inhibits HIV-1 Replication through Multiple Target Binding	128
Quantitation of Bacillus clausii in biological samples by real-time polymerase chain reaction.	127
Persistent symptomless human metapneumovirus infection in hematopoietic stem cell transplant recipients.	126
Anti-HIV-1 response elicited in rabbits by anti-idiotype monoclonal antibodies mimicking the CD4-binding site.	125
Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir.	125
Molecular epidemiology of KI and WU polyomaviruses in infants with acute respiratory disease and in adult hematopoietic stem cell transplant recipients.	125
Evolutionary characteristics of HIV type 1 variants resistant to protease inhibitors in the absence of drug-selective pressure.	124
Epidemiological, molecular and clinical features of enterovirus 109 infection in children and in adult stem cell transplant recipients.	123
Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL.	122
Efficacy of a multistep strategy for Helicobacter pylori eradication.	122
Cross-reactive pseudovirus-neutralizing anti-envelope antibodies coexist with antibodies devoid of such activity in persistent hepatitis C virus infection.	122
2-aminothiazolones as anti-HIV agents which act as gp120-CD4 Inhibitors	121
Viral tropism by geno2pheno as a tool for predicting CD4 decrease in HIV-1-infected naive patients with high CD4 counts.	121
Infection and coinfection of human rhinovirus C in stem cell transplant recipients.	120
The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy.	120
Two-year prospective study of single infections and co-infections by respiratory syncytial virus and viruses identified recently in infants with acute respiratory disease.	120
Persistent replication of severe acute respiratory syndrome coronavirus in human tubular kidney cells selects for adaptive mutations in the membrane protein.	119
In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir	118
HIV DNA loads, plasma residual viraemia and risk of virological rebound in heavily treated, virologically suppressed HIV-infected patients.	118
IL28B rs12979860 genotype as a predictor marker of progression to BKVirus Associated nephropathy, after kidney transplantation	118
The role of infections and coinfections with newly identified and emerging respiratory viruses in children.	117
Cloning and molecular characterization of a human recombinant IgG Fab binding to the Tat protein of human immunodeficiency virus type 1 (HIV-1) derived from the repertoire of a seronegative patient.	115
Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir.	114
Rifabutin-based Helicobacter pylori eradication 'rescue therapy'.	113
The new and less toxic protease inhibitor saquinavir-NO maintains anti-HIV-1 properties in vitro indistinguishable from those of the parental compound saquinavir.	110
Revealing enterovirus infection in chronic human disorders: An integrated diagnostic approach	106
Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression	104
Dynamic features of the selective pressure on the human immunodeficiency virus type 1 (HIV-1) gp120 CD4-binding site in a group of long term non progressor (LTNP) subjects.	102
Development and in Vitro Evaluation of a Microbicide Gel Formulation for a Novel Non-Nucleoside Reverse Transcriptase Inhibitor Belonging to the N-Dihydroalkyloxybenzyloxopyrimidines (N-DABOs) Family	101
Heterogeneity of the humoral anti-HCV/E2 response in persistently infected patients as demonstrated by divergent patterns of inhibition of the binding of anti-HCV/E2 human monoclonal antibodies.	93
Quantitative HIV-1 proviral DNA detection: a multicentre analysis.	93
Comparison of the artus HIV-1 QS-RGQ and VERSANT HIV-1 RNA 1.0 assays for quantitative detection of human immunodeficiency virus type 1 in plasma samples	92
Phage display for the production of human monoclonal antibodies against human pathogens.	86
Characterization of GBV-C infection in HIV-1 infected patients.	84
Humoral immune response against hepatitis C virus.	81
Molecular cloning of the first human monoclonal antibodies neutralizing with high potency swine-origin influenza A pandemic virus (S-OIV).	79
A phage display vector optimized for the generation of human antibody combinatorial libraries and the molecular cloning of monoclonal antibody fragments.	77
Sequence analysis of NS3 protease gene in clinical strains of hepatitis C virus.	77
Helicobacter pylori: a culprit in extraintestinal diseases?	76
Long-term study on symptomless human metapneumovirus infection in hematopoietic stem cell transplant recipients.	74
Phylogenetic internal control for HIV-1 genotypic antiretroviral testing.	74
Intra-host evolution of human immunodeficiency virus type 1 and viral fitness.	70
Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group.	68
Targeting patients' microbiota with probiotics and natural fibers in adults and children with constipation	56
Totale	8.573

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	27.887
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	27.887

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2019/2020	1.941	110	90	103	392	122	199	283	234	150	120	36	102
2020/2021	1.261	34	130	63	138	73	130	83	111	175	45	103	176
2021/2022	655	81	141	5	53	8	21	41	42	33	82	66	82
2022/2023	990	79	6	48	114	111	245	1	135	184	26	14	27
2023/2024	1.794	311	330	304	338	353	83	5	13	36	4	0	17
Totale													8.573